| abstract |
The present invention relates to monoclonal antibodies that specifically recognize B cell lymphoma cells and their uses. Specifically, the present invention provides a pharmaceutical composition for preventing or treating B-cell lymphoma comprising the monoclonal antibody, the monoclonal antibody, the B-cell lymphoma-containing composition comprising the monoclonal antibody, the B cell using the monoclonal antibody A method for providing information for diagnosis of lymphoma, comprising the steps of: i) the antibody, ii) the transmembrane domain, and iii) a CAR (chimeric antigen receptor) protein comprising the intracellular signaling domain, a recombinant vector expressing the CAR protein, Modified T cells, a pharmaceutical composition for the prophylaxis or treatment of B cell lymphoma comprising the CAR-modified T cells, and an antibody-drug conjugate conjugated with the monoclonal antibody and drug -drug conjugate. |